Retension Pharmaceuticals, Inc.

Retension Pharmaceuticals, Inc. is a US-based biopharmaceutical company focusing on innovative therapies to optimize blood pressure and enhance cardiovascular health. Founded in 2023 and headquartered in Falls Church, US, Retension Pharmaceuticals specializes in developing treatments for hypertension and cardiovascular disorders. The company has executed a total of 3 deals, with its latest funding round being a Series B In April 2025, Retension Pharmaceuticals, Inc.

raised USD 12. 89 million in series B funding from unspecified investors. The company has not undergone any significant changes in business strategy or structure since its inception. Retension Pharmaceuticals is dedicated to advancing the field of biopharmaceuticals with a focus on optimizing blood pressure and enhancing cardiovascular health.

The company's core product offerings include innovative therapies designed to manage hypertension and improve overall cardiovascular function. These products aim to address critical challenges faced by patients with cardiovascular conditions, providing effective solutions to help manage their health more effectively. Retension Pharmaceuticals serves a diverse clientele, including healthcare providers, hospitals, and specialty pharmacies, primarily targeting markets in North America and Europe. The end users of these products are patients diagnosed with hypertension and other cardiovascular disorders who benefit from enhanced blood pressure control and improved health outcomes.

Retention Pharmaceuticals generates revenue through a structured business model that includes partnerships with healthcare providers and direct sales to pharmacies. The company engages in transactions primarily through B2B relationships, supplying its innovative therapies to healthcare institutions and retail pharmacies. These transactions involve agreements where healthcare providers purchase the products at negotiated pricing, enabling them to dispense these therapies to patients in need. The revenue stream is bolstered by the strong demand for their flagship products, designed to address the critical issues surrounding blood pressure management and cardiovascular health.

The pricing structure for these products is aligned with industry standards, reflecting the value of the innovative therapies offered. The company will use the April 2025 funding to support the development of its product, accelerate its talent acquisition, and facilitate its global licensing. There are plans for upcoming product launches, which are expected to enhance their portfolio and address market needs. Additionally, the company aims to expand into new geographic regions, specifically targeting markets in Asia and South America by the end of 2026.